鼻到心的方法:揭示急性治疗的替代途径
Paraskevi Papakyriakopoulou1, Georgia Valsami1, Nikolaos P E Kadoglou2
1Laboratory of Biopharmaceutics and Pharmacokinetics, Section of Pharmaceutical Technology, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, 15771 Athens, Greece.
Biomedicines
|January 23, 2024
概括
鼻内药物输送为心血管紧急情况提供了快速的全身吸收,绕过了口服限制. 这种方法对急性心脏事件的更快治疗有希望.
科学领域:
- 药理学 药理学是指药理学的学科.
- 心脏病学 心脏病学
- 药物输送系统 药物输送系统
背景情况:
- 鼻内 (IN) 给药是一种快速全身药物吸收的新途径.
- 它通过绕过第一通代谢来管理急性心血管事件,提供了潜在的优势.
- 鼻腔粘膜的血管化和膜结构促进了有效的药物吸收.
研究的目的:
- 审查IN心血管药物治疗的演变和潜力.
- 评估急性心血管事件的IN药物输送,如心肌梗塞和心律失常.
- 为了突出IN管理的好处,在心血管紧急情况的口服途径.
主要方法:
- 关于IN心血管药物的临床前和临床研究的文献综述.
- 对心痛,心肌梗塞,高血压发作和心律失常的IN配方的评估.
- 对特异性药物的评估,如利帕米尔鼻喷剂,用于 supraventricular tachycardia.
主要成果:
- 临床前研究证实了用于心血管药物的IN注射的可行性.
- 临床试验表明,与口服药物相比,其生物可用性更好,作用更快.
- 埃特里帕米尔鼻喷剂显示出对心上高心率的治疗潜力.
结论:
- 通过IN途径可提供快速的全身吸收和心血管药物的快速起作用.
- 这种方法有助于在家庭环境下对急性心脏事件进行自我管理.
- 尽管临床数据有限,鼻到心的方法在心血管药物治疗中具有显著的临床潜力.
更多相关视频
相关概念视频
01:18Drug Delivery: Enteral Route
456
The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
456
01:29Acute Respiratory Failure-V
141
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
141
01:16Antianginal Drugs: Nitrates and β-Blockers
593
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
593
01:17Increased pulse rate
667
Tachycardia is a condition marked by an abnormally fast or irregular heart rate, surpassing the typical resting rate. In adults, tachycardia is characterized by a pulse rate ranging from 100 to 180 beats per minute. The increased heart rate can result in inadequate blood flow to various body parts, ultimately diminishing the oxygen supply to organs and tissues.
Many factors can elevate the risk of developing tachycardia. These include advanced age, a family history of arrhythmias, and an...
Many factors can elevate the risk of developing tachycardia. These include advanced age, a family history of arrhythmias, and an...
667
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
432
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
432
01:28Pneumonia IV: Management
331
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
331